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Summary
Background Quality of care is consistently shown to be inadequate in health-care settings in many low-income and 
middle-income countries, including in private facilities, which are rapidly growing in number but often do not have 
effective quality stewardship mechanisms. The SafeCare programme aims to address this gap in quality of care, using 
a standards-based approach adapted to low-resource settings, involving assessments, mentoring, training, and access 
to loans, to improve clinical quality and facility business performance. We assessed the effect of the SafeCare 
programme on quality of patient care in faith-based and private for-profit facilities in Tanzania.
Methods In this cluster-randomised controlled trial, health facilities were eligible if they were dispensaries, health 
centres, or hospitals in the faith-based or private for-profit sectors in Tanzania. We randomly assigned facilities (1:1) 
using computer-generated stratified randomisation to receive the full SafeCare package (intervention) or an 
assessment only (control). Implementing staff and participants were masked to outcome measurement and the 
primary outcomes were measured by fieldworkers who had no knowledge of the study group allocation. The primary 
outcomes were health worker compliance with infection prevention and control (IPC) practices as measured by 
observation of provider–patient interactions, and correct case management of undercover standardised patients at 
endline (after a minimum of 18 months). Analyses were by modified intention to treat. The trial is registered with 
ISRCTN, ISRCTN93644888.
Findings Between March 7 and Nov 30, 2016, we enrolled and randomly assigned 237 health facilities to the 
intervention (n=118) or control (n=119). Nine facilities (seven intervention facilities and two control facilities) closed 
during the trial and were not included in the analysis. We observed 29 608 IPC indications in 5425 provider–patient 
interactions between Feb 7 and April 5, 2018. Health facilities received visits from 909 standardised patients between 
May 3 and June 12, 2018. Intervention facilities had a 4·4 percentage point (95% CI 0·9–7·7; p=0.015) higher mean 
SafeCare standards assessment score at endline than control facilities. However, there was no evidence of a difference 
in clinical quality between intervention and control groups at endline. Compliance with IPC practices was observed in 
8181 (56·9%) of 14 366 indications in intervention facilities and 8336 (54·7%) of 15 242 indications in control facilities 
(absolute difference 2·2 percentage points, 95% CI –0·2 to –4·7; p=0·071). Correct management occurred in 
120 (27·0%) of 444 standardised patients in the intervention group and in 136 (29·2%) of 465 in the control group 
(absolute difference –2·8 percentage points, 95% CI –8·6 to –3·1; p=0·36).
Interpretation SafeCare did not improve clinical quality as assessed by compliance with IPC practices and correct case 
management. The absence of effect on clinical quality could reflect a combination of insufficient intervention 
intensity, insufficient links between structural quality and care processes, scarcity of resources for quality 
improvement, and inadequate financial and regulatory incentives for improvement.
Funding UK Health Systems Research Initiative (Medical Research Council, Economic and Social Research Council, 
UK Department for International Development, Global Challenges Research Fund, and Wellcome Trust).
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Quality of care has risen high up the global health policy 
agenda. Together with expanding coverage and financial 
protection, quality of care is a key component of health 
reforms inspired by universal health coverage.1,2 Poor 
quality of care is estimated to result in approximately 
5·7–8·4 million deaths per year in low-income and 
middle-income countries (LMICs),3 where patient care is 
consistently shown to be inadequate. In primary care in 
LMICs it is common for outpatients to receive less than 
half of the recommended clinical actions,2,4 diagnoses 
for serious conditions are frequently incorrect,5,6 and 
medicines are widely under-provided and over-provided.7 
Health-care-associated infections con tinue to be an 
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important threat to patient safety, reflecting poor infection 
prevention and control (IPC) practices.2,8
There are concerns regarding quality of care in both 
the public and private health-care sector.2 The private 
sector is a substantial and growing provider of health 
services in many LMICs, responsible for around 63–67% 
of health care for sick children and 30–39% of maternal 
health care when averaged across 70 LMICs.9 Such high 
use of private health care partly reflects the established 
use of private medicine retailers and the provision of 
private health care by faith-based organisation facilities,10 
but the use of for-profit private clinics and hospitals has 
grown rapidly in recent decades, reflecting urbanisation, 
the growth of the middle class, rising expectations of 
quality not met by the public sector, and empanelment of 
private facilities within social health insurance systems.11
Quality of care is extremely variable across such private 
health-care facilities,12,13 and there are concerns about 
the scarcity of effective quality stewardship mechanisms 
for this sector.14 Statutory regulation of private facilities 
is typically very weak, with rare inspection and 
erratic enforcement, reflecting inadequate resources and 
capacity at the national level.15 Although health-care 
accreditation systems can, in theory, complement or 
substitute regulation of the facilities to some degree, the 
standards required by international accreditation bodies 
seem unattainable and the process too expensive for the 
vast majority of private facilities in LMICs. Alternative 
strategies to improve the quality of care in private facilities 
have been tried, including provider training, social 
franchising, and quality improvement cycles.15 However, 
the evidence base on the effectiveness of these strategies 
is scarce. Although there is some evidence that social 
franchising improves quality as perceived by patients, 
there is no robust evidence that any of these strategies 
improve clinical quality of care in an operational setting.16
These quality-of-care concerns led to the development 
of the SafeCare model, an innovative approach that adapts 
international accreditation standards to low-resource 
settings and supports health facilities to attain higher 
standards, recognising improvement through stepwise 
formal certification.17 SafeCare is a multifaceted inter-
vention. At its heart are the SafeCare standards, a 
comprehensive set of measurable indicators, which are 
used to assess health facilities and assign them to one of 
five quality levels from the lowest (1) to the highest (5). 
The standards cover clinical care, ancillary services, and 
management processes, and are accredited by the 
International Society for Quality in Health Care, having 
been designed in partnership with the Joint Commission 
International and the Council for Health Service 
Accreditation of Southern Africa.18 SafeCare standards 
address the full range of a facility’s operations, in contrast 
to many other quality improvement interventions that 
focus on specific clinical areas or target individual 
clinicians.19 Following a SafeCare assessment, facilities 
receive a tailored quality improvement plan, with 
implementation supported through clinical and business 
training, mentoring visits, and access to loans. Facilities 
receive a repeat SafeCare assessment after 1–2 years, with 
the intention that they gradually progress through the 
quality levels. With multiple components to the 
intervention there are numerous ways to improve, but the 
essence of the theory of change is that a greater adherence 
to SafeCare standards will lead to improvements in 
clinical quality, and business support will improve the 
facility’s financial performance. The intention is to create 
a virtuous circle; improvements in quality attract more 
Research in context
Evidence before this study
We searched for studies English, published up to December, 
2019, that evaluated the effect of interventions working with 
private facilities on clinical quality of care in low-income and 
middle-income countries (LMICs), using PubMed, Web of 
Science, and Google Scholar (formal literature) and websites of 
key donor agencies, research institutions, private sector-focused 
consultancies, non-governmental organisations, and academic 
organisations including Private Health in Developing Countries, 
The World Bank, US Agency for International Development, 
Population Services International, Private Sector Partnerships 
One, Health Systems 20/20, Reproductive Health Vouchers, and 
the UK Department for International Development (grey 
literature), using terms related to the domains of “private”, 
“LMIC”, and a range of interventions (eg, “social franchising”). 
No evaluations of SafeCare or similar models in private facilities 
were identified. We reviewed controlled evaluations of 
accreditation and social franchising interventions, which have 
some similar components to SafeCare: three randomised 
controlled trials found no or weak efficacy with regard to clinical 
quality, while three non-randomised studies had mixed effects, 
and might have been affected by selection bias.
Added value of this study
This study is the first evaluation of the effect of SafeCare on 
clinical quality of care, and one of very few randomised controlled 
trials on any intervention aiming to improve quality in the private 
sector in LMICs. The SafeCare intervention led to a small 
improvement in adherence to SafeCare standards, but there was 
no effect on clinical quality of care.
Implications of all the available evidence
The SafeCare programme can improve structural quality, but 
there is no evidence that, at the intensity usually implemented, 
it has an effect on clinical quality of care. Improving clinical 
quality of care remains an important challenge and the 
evidence base does not yet provide guidance on which 
approaches are most promising.
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revenue from patients and institutional purchasers, and 
improved business performance facilitates greater 
investment in quality improvement. Launched in 2011, 
and currently the only programme of its kind, SafeCare 
has been implemented in 14 countries in sub-Saharan 
Africa, in over 2500 facilities, which receive over 5 million 
visits per month.
The objective of this study was to evaluate the 
effectiveness of SafeCare in improving clinical quality of 
care at the facility level. We chose to evaluate SafeCare in 
Tanzania, where it was being implemented on a large 
scale in private facilities across the country and with UK 
Government funding through the Human Development 
Innovation Fund. The private sector accounts for 29% of 
health facilities in Tanzania (15% faith-based and 14% for-
profit), including hospitals and primary level facilities 
(health centres and smaller dispensaries).20 Historically, 
public oversight of private health facilities has been 
weak, although more recently there has been a strong 
commitment to enhancing quality in both the public and 
private sectors,21 since the roll-out of the government star 
rating initiative in 2015, which involves the inspection of 




We did a cluster-randomised controlled trial in private 
health facilities (clusters) in mainland Tanzania. 
Facilities were screened and recruited by implementing 
partners of PharmAccess (a non-profit organisation 
enabling access to better health care for people in 
sub-Saharan Africa)  in Tanzania: the Association of 
Private Health Facilities in Tanzania (APHFTA), which 
represents mainly for-profit facilities, and the Christian 
Social Services Commission (CSSC), which represents 
mostly faith-based facilities. Facilities were recruited 
from the Northern, Eastern, Central, Southern, and 
Southern Highlands zones of Tanzania (Lake zone was 
excluded as SafeCare was already rolled out there before 
study commencement).
The study protocol was approved by the ethics 
committees of the Ifakara Health Institute (04–2016; 
Dar Es Salaam, Tanzania), the National Institute of 
Medical Research (IX/2415; Dar Es Salaam, Tanzania), 
and the London School of Hygiene & Tropical Medicine 
(10493; London, UK). Alongside this effectiveness 
study, we also did a process evaluation to understand 
implementation, mechanisms of effect, and context,23 
which we draw on in the Discussion.
Participants
Eligible facilities were dispensaries and health centres 
that were members of APHFTA, and dispensaries, health 
centres, and hospitals that were members of CSSC. 
Facilities were ineligible if they refused to provide consent 
to participate, provided specific services only (eg, mental 
health or maternity services), were tertiary hospitals, or 
had previously been exposed to SafeCare. We worked 
with APHFTA and CSSC to select a non-random list of 
280 potentially eligible facilities for participation in 
the study (appendix p 2). The partner organisations 
approached these facilities to confirm their eligibility, 
explain the study, and obtain written informed consent 
from the facility manager. Study facilities were widely 
dispersed across both urban and rural areas, in 18 regions 
of mainland Tanzania.
Health workers participating in the study comprised 
those interviewed for a facility survey, those whose IPC 
practices were observed, and those visited by standardised 
patients. For the facility survey and IPC observations, 
written informed consent was obtained from the health 
worker before the start of data collection. At the time of 
the facility survey, facility managers were also asked to 
consent to visits from undercover standardised patients at 
an unspecified date within the next 3 months. Patients 
participating in the study were those directly observed 
during patient–provider interactions, and those who gave 
an exit interview before leaving the facility. For the 
observations, all patients were eligible if they or their 
adult caretaker gave verbal informed consent. Individuals 
aged younger than 18 years were excluded if they were not 
accompanied by an adult caretaker. For the exit interviews, 
patients were eligible if they were aged at least 18 years or 
were accompanied by an adult caretaker, had received 
curative outpatient care (therefore excluding routine 
visits for growth checks, immunisations, or antenatal 
care), and had completed their visit to the facility 
(including collecting prescribed treatments and making 
payments). Written informed consent was obtained from 
the patient or caretaker before the start of the interview.
Randomisation and masking
We randomised facilities (clusters) to the SafeCare 
package (intervention) or an initial SafeCare assessment 
with no further support (control) in a ratio of 1:1. 
Randomisation was stratified by partner organisation, 
recruitment cohort, hospital or non-hospital, and geo-
graphical zone. Specifically, we randomly allocated health 
facilities to intervention or control, stratifying the sample 
so that the proportion allocated to each of the two groups 
was the same within each stratum. Randomisation of 
facilities was done using a computer-generated random 
number in Stata version 14.1.
A letter revealing the study group assignment was 
sealed in an envelope labelled with the facility name and 
given to a SafeCare quality assessor who opened the 
envelope to inform the facility manager of the allocation 
once written informed consent was given and the baseline 
SafeCare assessment was complete. PharmAccess staff, 
partner organisations, and facility participants were 
masked to study group allocation during recruitment and 
baseline assessment, but not for the rest of the study. 
They were also masked to outcome measurement—ie, 
See Online for appendix
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they did not know what clinical quality metrics they were 
to be assessed on.
Procedures
The SafeCare programme supports private health facilities 
to improve quality of care and business performance. 
The programme also includes quality-related policy 
support and advocacy at the health system level, but the 
trial intervention evaluated only the direct support to 
facilities. The SafeCare intervention was implemented 
by partners APHFTA and CSSC. Following initial sensi-
tisation activities, SafeCare assessments were done by the 
implementation staff in both intervention and control 
facilities at baseline and, after a minimum of 18 months, 
at endline. Control facilities received a simple report of 
their assessment, but no further support. Separate data 
collection was done by the research team at endline, 
including observations of IPC practices, standardised 
patient visits, a survey of facility managers, and patient 
exit interviews (appendix p 3).
The initial SafeCare assessment assessed 170 standards 
grouped into 13 service elements: governance and 
management, human resource management, patient 
rights and access to care, management of information, 
risk management, primary health care, inpatient care, 
surgery and anaesthesia, laboratory services, diagnostic 
imaging, medication management, facility management 
services, and support services. Quality assessors 
measured how well facilities met the criteria, awarding 
an overall score between 0 and 100, and a performance 
level of one to five, with higher scores indicating better 
results. Quality assessors were employees of PharmAccess 
and were typically clinicians (clinical officers or nurses) 
who had completed a 70 h training programme with 
PharmAccess.
Facilities in the intervention group received a quality 
improvement plan that highlighted specific areas for 
improvement, actions to be taken, and the facility staff 
member responsible; mentoring visits from quality 
assessors to monitor progress on implementation of the 
quality improvement plan; training on topics such as 
infection control, waste management, customer care, 
business management, record keeping, and patient 
rights; and the opportunity to apply to the Medical Credit 
Fund, which is also part of the PharmAccess Group, for 
underwritten loans to fund specific quality improvement 
activities.
Quality assessors provided direct support to the 
managers of facilities in the intervention group, in the 
form of in-person mentoring visits to facilities, onsite 
training sessions, and offsite classroom training sessions 
for groups of facilities, attended by managers and 
clinicians. A full-time business analyst, employed by 
the Medical Credit Fund, made facilities aware of the 
SafeCare service during regional meetings attended by 
managers, and supported the writing of business cases 
and loan applications. Mentoring visits were intended to 
be quarterly (at least five visits were expected to take 
place in the 18–24-month period between baseline and 
endline SafeCare assessments), and staff from each 
facility were expected to attend at least two training 
sessions (either onsite or in the classroom).
We measured health provider compliance with IPC 
practices using observations of provider–patient 
interac tions. 6 h of observation were done in each facility 
over the course of 1 day: 3 h in the consultation rooms, 
1·5 h in the laboratory, and 1·5 h in the injection or 
dressing room. Fieldworkers recorded every indication 
(situation in which an infection risk to either patient, 
provider, or both was presented) and action (taken to 
mitigate the risk) using a tool that we developed according 
to WHO guidelines and previous studies8,24,25 and adapted 
to Tanzanian standards.26 The data were double entered on 
tablets using ODK Collect version 1.12.1. Health providers 
and patients were asked for written consent to participate 
in the study before observation commenced, but they 
were not informed of the focus on IPC practices or shown 
the tool. On the same day as observation, a survey of the 
health facility was done with the facility manager or 
representative, during which facility characteristics, 
patient numbers, and facility revenue were recorded. Also, 
up to eight patients per facility were given an exit interview. 
Implementation staff and study fieldworkers  were not 
present at the same facility simultaneously.
Standardised patients were undercover healthy 
fieldworkers, trained to present at health facilities 
reporting specific symptoms and medical history, and to 
record the care they received. We describe the methods 
and the protocol for standardised patient safety in more 
detail in the appendix (pp 4–24). Briefly, on the basis of 
predefined selection criteria and a systematic review of the 
literature, we developed four standardised patient cases: 
asthma, non-malarial febrile illness, tuberculosis, and 
upper respiratory tract infection. Case descriptions and 
their corresponding correct management definitions are 
given in the appendix (p 4). Standardised patients were 
trained for 2 weeks, with extensive piloting and testing to 
ensure faithful reproduction of cases and recording of 
data. Each facility received each of the four standardised 
patient cases once, within the 3 months following consent 
being given. Standardised patients completed a debriefing 
questionnaire on a smartphone using ODK Collect 
version 1.12.1 immediately after the visit, and supervisors 
verified the information with the standardised patient the 
same day. A follow-up telephone survey was done with 
facility managers to assess whether any standardised 
patients were detected (appendix pp 21–22).
In terms of contamination, no control facilities 
received a quality improvement plan or mentoring visits, 
and seven control facilities attended some training. In 
practice, both intervention and control facilities had the 
opportunity to apply for a Medical Credit Fund loan, and 
two control facilities obtained such a loan during the 
study period.
For the SafeCare website see 
www.safe-care.org
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Outcomes
The two prespecified primary outcomes of the trial 
were observed compliance of health workers with IPC 
practices and correct case management of standardised 
patients at 18–24 months. The choice of outcomes 
reflected close consultation with staff involved in 
SafeCare’s design and implementation, to capture the 
programme’s broad aim of improving clinical quality of 
care, together with its emphasis on IPC practices.
Compliance with IPC practices was defined as the 
proportion of indications for which a correct action was 
done.8 Each of the 21 potential indications had a 
corresponding IPC action (appendix pp 29–30). For 
example, for each patient having blood drawn (indication), 
a new needle was required (action). Indications were 
coded as either compliant or non-compliant (binary).
Correct case management was defined as the 
proportion of standardised patients who were managed 
in accordance with the national standard treatment 
guidelines27 (appendix p 4). The definition of correct 
management was case-specific and it was coded as a 
binary outcome (correct or incorrect).
Secondary outcomes were the facility SafeCare assess-
ment score (based on adherence to the 170 criteria, as 
described previously); patient experience-of-care score 
(based on responses to 21 Likert questions in the patient 
exit interview); patient out-of-pocket spending (including 
any consultation fee, and expenditure on medications 
and laboratory tests as measured by the standardised 
patients); facility caseload per month (measured by the 
facility survey using facility records from each medical 
department for the 3 preceding months); and facility 
revenue per month (measured by the facility survey 
using facility records on each income source for the 
3 preceding months). The methods for measuring the 
secondary outcomes are described in more detail in 
the appendix (pp 30–32). Management quality was a 
prespecified secondary outcome, and will be reported 
elsewhere. 
Statistical analysis
We planned to recruit 240 health facilities. For compliance 
with IPC practices, on the basis of estimated compliance 
of 31% in the control group8 and an assumed intracluster 
correlation coefficient of 0·1, a sample size of 120 facilities 
in each of the two groups with 115 indications observed 
in each facility was estimated to provide 80% power to 
detect an absolute increase of 5·6 percentage points in 
the intervention group versus the control group at a 5% 
level of significance. For correct case management, on 
the basis of an estimate of 52% in the control group and 
an assumed intracluster correlation coefficient of 0, a 
sample size of 120 facilities in each of the two groups 
with four standardised patient visits in each facility was 
estimated to provide 80% power to detect an absolute 
increase of 9·0 percentage points in the intervention 
group versus the control group at a 5% level of 
significance. These calculations conservatively took no 
account of the stratified randomisation.
The analysis of the primary outcomes accounted 
for clustering using a multilevel mixed-effects logistic 
regression that included facility random effects and 
stratum fixed effects. A modified intention-to-treat 
analysis was done for all endpoints, and included all 
facilities that remained open until the corresponding 
endline assessment. We report effect sizes as both 
marginal (absolute) effects and odds ratios. For 
compliance with IPC practices, analysis was at the level 
of indication. The primary outcome was a dichotomous 
outcome that is present if the health worker undertook 
the correct IPC action corresponding to the indication, as 
defined in the appendix (pp 29–30). For correct case 
management, analysis was at the level of standardised 
patient visit with data pooled across the four cases. The 
primary outcome was a dichotomous outcome that is 
present if a standardised patient received correct case 
management during a visit as defined in the appendix 
(p 4). For comparison of correct case management by 
individual case, we used penalised maximum likelihood 
logistic regression to address the problem of separation 
within strata.28 We also report results from a series of 
sensitivity checks and pre specified subgroup analyses, 
including compliance with IPC practices by safety 
domain (appendix pp 40–49). Although not prespecified, 
Figure 1: Trial profile
At least one provider–patient interaction was observed in 223 facilities (five facilities had no eligible patients) and at 
least one IPC indication in 220 facilities (three facilities had interactions with no indications). At least one standardised 
patient case was assessed in 227 facilities. IPC=infection prevention and control practices. SP=standardised patients. 
118 facilities assigned to intervention
111 facilities evaluated at endline
 5 evaluated SPs only
 106 evaluated IPC and SPs
7 facilities closed
280 facilities assessed for eligibility  
237 facilities recruited and randomised 
43 ineligible or unwilling to participate
119 facilities assigned to control 
117 facilities evaluated at endline
 1 evaluated IPC only
 3 evaluated SPs only
 113 evaluated IPC and SPs
 
2 facilities closed
109 received second assessment 
2 facilities closed
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we also examined correct management by standardised 
patient case. Secondary outcomes measured at the facility 
level were analysed using ordinary least squares, with 
the inclusion of stratum fixed effects. The patient 
experience-of-care score and patient out-of-pocket 
spending were analysed using a linear mixed-effects 
model that included facility random effects and stratum 
fixed effects. We made no adjustment for multiplicity of 
testing. Missingness was assumed to be at random and 
missing values were not imputed. Analyses were done 
with Stata version 14.1. The trial is registered at ISRCTN 
(ISRCTN93644888).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Facilities were recruited from March 7 to Nov 30, 2016. 
280 facilities were selected as potentially eligible. After 
approaching the facilities, 43 (15%) were ineligible or 
unwilling to participate, leaving a total of 237 facilities 
participating, of which 118 were randomly assigned 
to the intervention group and 119 to the control group 
(figure 1). Compliance with IPC practices was assessed 
between Feb 7 and April 5, 2018, (mean overall follow-up 
period of 21·2 months [SD 2·1]; 21·2 months [1·9] in 
the intervention facilities and 21·2 months [2·2] in the 
control facilities) in 228 facilities (eight facilities had 
perman ently closed since recruitment and one was closed 
for renovations). IPC observations in eight (4%) of the 
228 facilities resulted in no indications being observed. 
29 608 IPC indications were observed (14 366 in the 
intervention group and 15 242 in the control group) in 
5425 provider–patient interactions. Correct manage ment 
of standardised patients was assessed between May 3 and 
June 12, 2018 (mean follow-up period of 23·8 months 
[SD 2·0]; 23·8 months [1·8] in the intervention facilities 
and 23·8 months [2·2] in the control facilities), in 
227 facilities (one facility, assigned to the control group 
was owned by a private company and served only 
their employees so standardised patients could not visit 
undercover). 909 standardised patient visits were done 
(444 visits in the intervention group and 465 in the control 
group). The endline SafeCare assessment was done 
between Oct 12, 2017, and Dec 3, 2018, (mean follow-up 
period of 23·4 months [SD 1·4]; 23·5 months [1·6] in the 
intervention facilities and 23·4 months [1·2] in the control 
facilities) in 221 facilities (a further eight facilities closed 
down and one facility reopened).
118 (100%) facilities in the intervention group received 
a quality improvement plan based on a visit from a 
quality assessor. Fidelity was lower with respect to 
mentoring visits (mean 3·1 visits [SD 1·5] of five 
expected) and training sessions (mean 0·6 [0·8] of two 
expected, although informal training during mentoring 
visits was generally not recorded). Only two of the 
118 intervention facilities received a loan as part of the 
intervention.
There was no difference in the baseline SafeCare 
score between the two randomised groups (table 1). The 
intervention and control facilities were also well balanced 
with respect to other baseline characteristics. 132 (56%) of 
the 237 facilities were dispensaries. They were spread 
across urban, periurban, and rural areas, with the majority 
(194 [81%] of 237) located outside the commercial capital, 
Dar es Salaam. Infrastructure and staffing numbers 
reflected the small or medium size of many facilities. The 
median number of patient visits per clinician per day 
was 8·7 (IQR 4·3–16·7) in the intervention group, and 
8·2 (3·8–14·2) in the control group. The age and sex of 
patients observed during IPC observations were similar in 
the intervention and control groups (appendix p 39). Nine 
facilities were lost to follow-up (7 in the intervention group 
and 2 in the control group), although there was no 
evidence that attrition affected baseline balance between 
trial groups (appendix p 36). We found no strong evidence 








SafeCare assessment score* 41·8% (12·5) 41·7% (12·2)
Partner organisation
APHFTA 60 (51%) 59 (50%)
CSSC 58 (49%) 60 (50%)
Facility level
Dispensary 65 (55%) 68 (57%)
Health centre 35 (30%) 33 (28%)
Hospital 18 (15%) 18 (15%)
Facility location
Inside Dar es Salaam, Tanzania 22 (19%) 21 (18%)
Outside Dar es Salaam, Tanzania 96 (81%) 98 (82%)
Facility location type
Urban 38 (32%) 35 (29%)
Periurban 32 (27%) 34 (29%)
Rural 48 (41%) 50 (42%)
Facility opening hours
Open 24 h, 7 days a week 72 (61%) 76 (64%)
Staffing and infrastructure 
Number of medical doctors 0 (1–2) 1 (0–2)
Number of clinical officers 2 (1–3) 1 (1–2)
Number of nurses and midwives 2 (1–5) 3 (1–5)
Number of total staff 14 (9–27) 15 (9–27)
Number of consulting rooms 2 (1–3) 2 (1–3)
Number of inpatient admission beds 0 (0–45) 0 (0–30)
Data are mean (SD), n (%), and median (IQR). APHFTA=Association of Private 
Health Facilities in Tanzania. CSSC=Christian Social Services Commission. *% of 
maximum score. 
Table 1: Baseline characteristics of intervention and control facilities
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In the intervention group, 8181 (56·9%) of 14 366 
indications were met with IPC-practice compliance and 
in the control group 8336 (54·7%) of 15 242 indications 
were met with IPC-practice compliance, with an absolute 
difference of 2·2 percentage points (95% CI –0·2 to 4·7; 
p=0·071; table 2) and an intracluster correlation 
coefficient of 0·030. In the adjusted analysis, controlling 
for age, sex, and indication, IPC-practice compliance 
was 2·3 percentage points higher (0·3 to 4·4; p=0·028) 
in the intervention group than in the control group. In 
the intervention group, 120 (27·0%) of 444 standardised 
patients received correct case management, compared 
with 136 (29·2%) of 465 in the control group, with an 
absolute difference of –2·8 percentage points (95% CI 
–8·6 to 3·1; p=0·36; table 2) and an intracluster 
correlation coefficient of less than 0·0001. The results 
remained similar when we adjusted the analysis for 
standardised patient fieldworker and case, weighted the 
data using patient volume, or excluded the 48 (5·2%) of 
909 standardised patient visits categorised as detected in 
the follow-up telephone survey (appendix p 44). Results 
of the post-hoc subanalyses of IPC-practice compliance 
by safety domain and correct case management by type 
of case also showed no significant differences between 
groups (table 2); prespecified subgroup analyses for 
the primary endpoints are presented in the appendix 
(pp 45–46).
Facilities in the intervention group had a mean endline 
SafeCare assessment score of 55·2% (95% CI 52·3–58·1) 
compared with 50·8% (48·2–53·3) for facilities in the 
control group (figure 2). The difference was 4·4 
percentage points (95% CI 0·9–7·7; p=0·015). The 
increase in SafeCare score between baseline and endline 
was 12·8 percentage points (95% CI 10·1–15·4) in the 
intervention group, compared with 8·7 (6·7–10·7) in 
the control group, with a between-group difference 
in score change of 4·0 percentage points (0·8–7·1; 
p=0·014). The increase in the SafeCare score reflected 
improvements in a number of service elements: human 
resource management, patient rights and access to care, 
risk management, inpatient care, and support services 
(appendix p 37). At endline, 9 (8%) of 109 intervention 
facilities and 7 (6%) of 112 control facilities had attained 
SafeCare level 4, and none in either group had attained 
level 5.
Table 3 reports the results of the other secondary 
outcomes. Differences between the trial groups in 
monthly patient volumes and monthly facility revenue 
Intervention facilities Control facilities Absolute percentage 
point difference 
(95% CI)
OR (95% CI) p value 
IPC compliance* 8181/14 366 (56·9%) 8336/15 242 (54·7%) 2·2% (–0·2 to 4·7) 1·10 (0·99 to 1·21) 0·07
Hand hygiene compliance 361/4201 (8·6%) 295/4454 (6·6%) 1·1% (–0·7 to 2·8) 1·35 (0·84 to 2·17) 0·23
Glove use compliance 2539/3369 (75·4%) 2576/3539 (72·8%) 3·5% (–2·7 to 9·8) 1·22 (0·86 to 1·73) 0·27
Injection and blood draw 
compliance
4114/4228 (97·3%) 4306/4515 (95·4%) 0·7% (–0·2 to 1·6) 1·61 (0·89 to 2·92) 0·14
Disinfection compliance 16/416 (3·8%) 24/426 (5·6%) 0·1% (–1·6% to 1·7) 1·07 (0·28 to 4·06) 0·93
Waste segregation compliance 1183/2152 (55·0%) 1196/2308 (51·8%) 4·2% (–2·4 to 10·8) 1·19 (0·90 to 1·57) 0·22
Overall correct case management 
of standardised patients†
120/444 (27·0%) 136/465 (29·2%) –2·8% (–8·6 to 3·1) 0·87 (0·65 to 1·17) 0·36
Asthma 7/111 (6·3%) 6/116 (5·2%) 1·2% (–5·2 to 7·6) 1·23 (0·42 to 3·55) 0·71
Non-malarial febrile illness 79/111 (71·2%) 85/117 (72·6%) –1·9% (–13·8 to 10·0) 0·91 (0·50 to 1·64) 0·75
Tuberculosis 23/111 (20·7%) 33/116 (28·4%) –9·0% (–20·0 to 2·1) 0·60 (0·32 to 1·13) 0·12
Upper respiratory tract infection 11/111 (9·9%) 12/116 (10·3%) –1·1% (–9·3 to 7·1) 0·89 (0·38 to 2·08) 0·80
Data are n/N (%), unless otherwise specified. For standardised patients, the denominator in the control group varies across cases because one facility received 
two standardised patients with non-malarial febrile illness. IPC=infection prevention and control practices. OR=odds ratio. *Assessed in 106 facilities in the intervention 
group and 114 facilities in the control group. †Assessed in 111 facilities in the intervention group and 116 facilities in the control group. 
Table 2: Primary outcomes at endline
Figure 2: Change in SafeCare assessment score over time in the intervention 
and control groups
Error bars=95% CI.
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were large and economically meaningful but the point 
estimates were imprecise, with CIs that included both 
the possibility of no effect, or a large and important 
effect. There was no significant difference in patient 
experience of care and patient out-of-pocket spending. 
We carried out an exploratory cross-sectional analysis 
of our own data to assess associations between SafeCare 
level and clinical quality. Pooling intervention and 
control facilities, we found a modest positive correlation 
between SafeCare level and correct standardised 
patient management (Spearman’s rank correlation 
coefficient 0·225, p=0·0008), and no association between 
SafeCare level and IPC-practice compliance (p=0·13).
Discussion
We did a randomised controlled trial of an intervention 
package designed to address quality of care in a holistic 
manner in health facilities in a low-resource setting. The 
intervention started from a very low base in terms of 
clinical quality; IPC-practice compliance in the control 
group at endline was observed in only 55% of indications, 
and correct management occurred in just 29% of 
standardised patients. The intervention had a modest 
positive effect (an increase of 4·4 percentage points) on 
compliance with SafeCare standards, as measured by the 
SafeCare assessment score. However, this increase in 
SafeCare score did not translate into an improvement in 
clinical quality, with 57% of indications being compliant 
with IPC practices and only 27% of standardised patients 
receiving correct case management in the intervention 
group. The findings are perhaps unsurprising given 
the small effect of the SafeCare package on SafeCare 
score results.
Turning to the strengths and limitations of the 
evaluation, generalisability was enhanced by the study’s 
large scale, wide geographical reach, inclusion of 
both faith-based and for-profit facilities, and real-world 
operational conditions. By design, control facilities 
received a copy of their baseline SafeCare report, but 
as the report was not accompanied by any explanation 
or further support, implementers felt it was very 
unlikely to have led to a substantial quality improvement 
in most facilities. A key strength of the evaluation 
was the use of robust measures of clinical quality of 
care: IPC observation and standardised patients. 
Process measures such as these directly assess provider 
behaviour and adherence to established clinical guide-
lines, and are therefore much more closely related 
to health out comes than structural measures. IPC 
observations were potentially susceptible to the 
Hawthorne effect,29 in which study participants’ 
awareness of being observed causes them to alter their 
behaviour. However, when we examined the relationship 
between compliance and order number of patients 
observed, we found no strong evidence of such an effect 
(appendix pp 41–43). The use of standardised patients 
has a particular advantage as a quality measurement 
tool, allowing comparison across facilities without 
confounding due to mixing of patients and cases, and 
allowing facilities to be blinded to measurement 
and fieldworkers masked to random assignment. A 
limitation of the study was that the cases presented by 
the standardised patients needed to have no visible 
symptoms or require invasive examinations. More 
generally, in our primary outcomes, it was not possible 
to capture all types of clinical improvement that might 
be expected from the intervention (eg, we did not assess 
inpatient care or emergency referrals). However, the 
measures were chosen to be core to the intervention 
scope, and of high priority in public health terms.
We did not do a costing of the intervention, but it is 
possible to roughly estimate the cost per facility on the 
basis of the overall SafeCare expenditure for Tanzania, 
of which the intervention group facilities were part. 
The total grant was for US$3·9 million for 5 years, and 
466 facilities were enrolled. Excluding $158 000 not 
Intervention facilities Control facilities Difference (95% CI) p value
n Mean (SD) n Mean (SD)
Facility patient visits per month 111 1024 (1447) 117 822 (1050) 145 (–111 to 401) 0·27
Outpatient visits 111 936 (129) 117 735 (903) 145 (–90 to 380) 0·22
Inpatient admissions 111 89 (199) 117 87 (193) –1 (–34 to 33) 0·97
Facility revenue, US$* per month 105 8833 (18 483) 106 6840 (10 194) 1664 (–2061 to 5389) 0·38
Cash user fee revenue 107 5143 (14 683) 108 3999 (6057) 790 (–2167 to 3748) 0·60
Insurance revenue 107 2850 (6886) 111 2152 (4560) 582 (–771 to 1935) 0·40
Other revenue sources 110 868 (3434) 114 541 (1899) 270 (–387 to 927) 0·42
Patient experience of care† 668 90·8% (8·9) 733 90·7% (8·6) 0·2 (–1·0 to –1·4) 0·72
Patient out-of-pocket spending, US$* 668 5·17 (8·37) 733 4·91 (7·90) 0·13 (–1·41 to 1·68) 0·87
Data are n (number of facilities or number of patients accordingly) or mean (SD), unless specified. For facility-level outcomes, the difference is from an ordinary least squares 
regression that included stratum fixed effects. The p value is based on robust standard errors. For patient-level outcomes, the difference is from a linear mixed-effects model 
that included facility random effects and stratum fixed effects. *Converted from Tanzanian shillings using 2018 World Bank exchange rate, 1 US$=2263·781 TZS. †% of 
maximum score. 
Table 3: Secondary outcomes at endline
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directly related to the facility-level intervention implies a 
cost of just over $8000 per facility.
Although no other evaluations of SafeCare-style 
programmes were identified in private facilities in 
LMICs, two evaluations of similar accreditation 
programmes for private hospitals had similar results to 
the current study. A randomised controlled trial in 
South Africa30 and a non-randomised controlled study 
in Zambia31 both found that the accreditation programme 
had an effect on accreditation score, but almost no effect 
on other quality indicators. No other robust studies were 
identified.32 Two randomised controlled trials of social 
franchising in private facilities in India also found no or 
weak effect on quality of care.33,34 A study of SafeCare in 
public facilities in Nigeria did not measure clinical 
quality-of-care outcomes, but found that SafeCare was 
associated with short-term, but not sustained, increases 
in some SafeCare standards.35
Quality of care was poor in both intervention and 
control groups. Less than a third of standardised patients 
in both groups received the correct care for their 
condition, with particularly low rates for those presenting 
with asthma and upper respiratory tract infection 
(table 2). Compliance with IPC practices was particularly 
low for hand hygiene, disinfection, and waste segregation, 
although it was high for injection and blood draws 
(table 2); further results are published elsewhere.36 Major 
deficiencies in quality of care have been reported in 
similar standardised patient studies in other LMICs,5,6,37 
and in a similar IPC study from Kenya.8 Poor quality of 
care is unlikely to be explained by facilities being too 
busy given the estimated median number of patient 
visits per clinician per day (8·4 per facility).
To explore the reasons for the absence of improvement 
on clinical quality, we consider the fidelity and quality of 
implementation, contextual factors, and the functioning 
of the expected causal mechanisms.23 We draw on the 
process evaluation (to be published separately), which 
involved a review of administrative data and interviews 
with facilities, implementing staff, and other stakeholders.
Facility staff were positive about SafeCare. They found 
the SafeCare standards well conceived and appreciated 
their holistic nature across the facility, although some 
smaller facilities perceived the standards as very 
demanding. The staff praised the clarity of the quality 
improvement plans, and found implementing staff 
friendly and helpful, particularly valuing mentorship 
visits as important for guidance and morale. The main 
concern of facility staff was the infrequency of mentoring 
visits, which partly reflected the relatively low intensity of 
the planned intervention, together with lower than 
planned implementation: facilities received less than 
two-thirds of planned mentoring visits and training 
sessions. Implementation staff explained that a key factor 
behind lower than expected implementation was delays 
in receiving their budget from the funder. Implementation 
staff also highlighted the challenges of reaching some 
remote facilities, and the reluctance of some facility 
staff to attend classroom training without compensation. 
However, this intensity of support is not atypical of 
SafeCare elsewhere in Africa.
There was particularly low uptake of loans to help 
facilities pay for any substantial upgrading required, 
obtained by only two intervention facilities, both for-
profit, late in the intervention period. Faith-based 
facilities generally could not take loans because church 
property could not be used as collateral. Low uptake in 
for-profit facilities was said to reflect initial problems 
faced by PharmAccess in establishing relationships with 
banks, facilities’ poor financial records and credit history, 
and their concerns about high interest rates, the duration 
of the application process, and the general economic 
outlook.
In terms of contextual factors, many facilities felt that 
the deterioration in Tanzania’s economic situation 
negatively affected facility incomes, which might have 
discouraged investment, and CSSC facilities reported 
that government support to faith-based facilities had 
been reduced. Both intervention and control facilities 
were exposed to a range of other quality-related activities 
during the study period. This included regular super-
vision from district health teams, quality improvement 
programmes run by other non-governmental organi-
sations often for specific health areas (73% of facilities 
reported participating in at least one such programme), 
and the government’s star rating assessments. These 
assessments were based on a similar but more narrow 
assessment of structural quality than SafeCare, and also 
involved a quality improvement plan, but no training 
or mentoring. Nearly all facilities had a star rating 
assessment during our study period, and facilities were 
concerned that a poor star rating assessment could risk 
facility closure. Empanelment of private facilities within 
Tanzania’s social health insurance mechanism, the 
National Health Insurance Fund, was also increasing 
over the study period. Although participation in quality-
related programmes was balanced between study groups 
(appendix p 47), it is possible that other support activities 
dampened the measured effect of SafeCare as both 
intervention and control facilities responded to other 
programmes, perhaps partly explaining the improvement 
of 8·7 percentage points in mean SafeCare assessment 
score in the control group.
There could also be weaknesses in hypothesised 
intervention causal mechanisms. The SafeCare approach 
rests on changes in structural quality (the SafeCare 
score) leading to changes in care processes. However, 
evidence has shown that structural quality is often poorly 
correlated with process quality.38 Cross-sectional analysis 
of our own data provided mixed evidence on this point: 
we found a modest positive correlation between SafeCare 
level and correct standardised patient management, and 
no association between SafeCare level and IPC -practice 
compliance. At endline, only 16 (15%) of 237 facilities had 
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reached SafeCare level 4 and none had reached level 5; 
senior SafeCare implementation staff argued that the 
links between structure and clinical quality are likely to 
be stronger as facilities progress to these higher levels, 
when they have the basics in place and focus more on 
adherence to clinical standards.
The intervention theory also relies on facilities being 
able to afford to improve standards. Although standards 
had negligible budget implications, smaller facilities 
were said to struggle to pay for more qualified staff, or a 
regular supply of IPC-practice materials. Finally, a key 
assumption is that facility staff will be motivated to 
increase compliance with SafeCare standards, either 
because of intrinsic concern for quality of care, or 
because they view SafeCare as good business sense. 
However, the link between SafeCare standards and 
increased facility income could be tenuous if patients 
cannot easily perceive quality improvements or if 
providers do not expect patients to be sensitive to 
improvements. Stronger external incentives might 
enhance motivation—eg, if SafeCare scores were directly 
linked to facility empanelment or reimbursement in 
social health insurance, or to regulatory penalties.39,40 It is 
important to consider quality improvement as a systems-
level issue, requiring not only behaviour change at the 
facility level, but also better preservice education, 
coordination across quality improvement mechanisms, 
and appropriate integration with health financing, 
procurement, and regulatory systems.
Quality of care was low in both intervention and control 
facilities, highlighting the importance of developing 
strategies to improve quality of care at the provider 
and system levels. However, although the SafeCare 
intervention led to modest improvements in SafeCare 
assessment scores, no effect was seen on clinical quality 
of care. These findings indicate that a higher burden 
of proof should be placed on policy makers and 
funders looking to invest in such interventions. Further 
experimentation and evaluation is clearly needed to 
identify effective and affordable quality improvement 
approaches, with possible strategies including increased 
intervention intensity using digital approaches, more 
careful selection of facilities for enrolment, creation of 
stronger financial or regulatory incentives for quality 
improvement, and increased focus on improving clinical 
care processes.
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